K Ji1, L J Zhao, W S Liu, Z Y Liu, Z Y Yuan, Q S Pang, J Wang, P Wang. 1. Department of Pain Relief, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Abstract
OBJECTIVE: To evaluate the clinical efficacy and safety of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small-cell lung cancer (LANSCLC). METHODS: 48 patients with LANSCLC treated with SIB-IMRT from January 2010 to April 2012 were retrospectively analysed. A radiation dose of 45-63 Gy (median dose, 51.58 Gy) was delivered to the planning target volume (1.8-2.0 Gy daily fractions) simultaneously with 55.0-74.2 Gy (median dose, 63 Gy) to the planning gross tumour volume (2.00-2.25 Gy daily fractions). 45 patients received concurrent/sequential chemotherapy. The overall survival (OS), locoregional recurrence-free survival (LRFS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Treatment-related pneumonitis and oesophagitis were graded according to the Common Terminology Criteria for Adverse Events v. 4.0. RESULTS: By 1 July 2013, 29 of the 48 patients were dead. The median follow-up time for the survivors was 28 months (19-44 months). The median OS and PFS were 21 and 14 months, respectively. The median LRFS time was not reached. The 2-year LRFS, OS and PFS were 62.5%, 45.1% and 28.0%, respectively. Two patients experienced Grade 3 treatment-related pneumonitis, two patients experienced Grade 5 treatment-related pneumonitis and two patients had ≥Grade 3 oesophagitis. CONCLUSION: SIB-IMRT appears to be an effective therapeutic option in patients with LANSCLC and warrants further evaluation with increased number of patients in prospective clinical trials. ADVANCES IN KNOWLEDGE: This study explores the feasibility of delivering tumoricidal doses of radiation to primary lesions in non-small-cell lung cancer.
OBJECTIVE: To evaluate the clinical efficacy and safety of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small-cell lung cancer (LANSCLC). METHODS: 48 patients with LANSCLC treated with SIB-IMRT from January 2010 to April 2012 were retrospectively analysed. A radiation dose of 45-63 Gy (median dose, 51.58 Gy) was delivered to the planning target volume (1.8-2.0 Gy daily fractions) simultaneously with 55.0-74.2 Gy (median dose, 63 Gy) to the planning gross tumour volume (2.00-2.25 Gy daily fractions). 45 patients received concurrent/sequential chemotherapy. The overall survival (OS), locoregional recurrence-free survival (LRFS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Treatment-related pneumonitis and oesophagitis were graded according to the Common Terminology Criteria for Adverse Events v. 4.0. RESULTS: By 1 July 2013, 29 of the 48 patients were dead. The median follow-up time for the survivors was 28 months (19-44 months). The median OS and PFS were 21 and 14 months, respectively. The median LRFS time was not reached. The 2-year LRFS, OS and PFS were 62.5%, 45.1% and 28.0%, respectively. Two patients experienced Grade 3 treatment-related pneumonitis, two patients experienced Grade 5 treatment-related pneumonitis and two patients had ≥Grade 3 oesophagitis. CONCLUSION: SIB-IMRT appears to be an effective therapeutic option in patients with LANSCLC and warrants further evaluation with increased number of patients in prospective clinical trials. ADVANCES IN KNOWLEDGE: This study explores the feasibility of delivering tumoricidal doses of radiation to primary lesions in non-small-cell lung cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A L Uitterhoeve; J S Belderbos; M G Koolen; P J van der Vaart; P T Rodrigus; J Benraadt; C C Koning; D González González; H Bartelink Journal: Eur J Cancer Date: 2000-03 Impact factor: 9.162
Authors: Feng-Ming Kong; Randall K Ten Haken; Matthew J Schipper; Molly A Sullivan; Ming Chen; Carlos Lopez; Gregory P Kalemkerian; James A Hayman Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Tae Hyun Kim; Kwan Ho Cho; Hong Ryull Pyo; Jin Soo Lee; Jae Ill Zo; Dae Ho Lee; Jong Mog Lee; Hyae Young Kim; Bin Hwangbo; Sung Yong Park; Joo Young Kim; Kyung Hwan Shin; Dae Yong Kim Journal: Radiology Date: 2005-02-09 Impact factor: 11.105
Authors: Dirk De Ruysscher; Stofferinus Wanders; Erik van Haren; Monique Hochstenbag; Wiel Geeraedts; Irwan Utama; Jean Simons; Jo Dohmen; Ali Rhami; Ulrich Buell; Paul Thimister; Gabriel Snoep; Liesbeth Boersma; Tom Verschueren; Angela van Baardwijk; Andre Minken; Søren M Bentzen; Philippe Lambin Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-15 Impact factor: 7.038
Authors: José Belderbos; Lon Uitterhoeve; Nico van Zandwijk; Huub Belderbos; Patrick Rodrigus; Paul van de Vaart; Allan Price; Nico van Walree; Catherine Legrand; Sonia Dussenne; Harry Bartelink; Giuseppe Giaccone; Caro Koning Journal: Eur J Cancer Date: 2006-11-03 Impact factor: 9.162
Authors: A Fondevilla Soler; J L López-Guerra; M Dzugashvili; P Sempere Rincón; A Sautbaet; P Castañeda; J M Díaz; J M Praena-Fernandez; E Rivin Del Campo; I Azinovic Journal: Clin Transl Oncol Date: 2017-06-06 Impact factor: 3.405
Authors: Jing You; Dan Yang; Dongming Li; Leilei Jiang; Rong Yu; Huiming Yu; Bo Xu; Weihu Wang; Anhui Shi Journal: Zhongguo Fei Ai Za Zhi Date: 2019-11-20
Authors: Li Ma; Bo Qiu; QiWen Li; Li Chen; Bin Wang; YongHong Hu; MengZhong Liu; Li Zhang; Yan Huang; XiaoWu Deng; YunFei Xia; MaoSheng Lin; Hui Liu Journal: Radiat Oncol Date: 2018-07-17 Impact factor: 3.481